Cargando…

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients

BACKGROUND: Tamoxifen is considered a prodrug of its active metabolite endoxifen, which is dependent on the CYP2D6 and CYP3A enzymes. Tamoxifen pharmacokinetic variability influences endoxifen exposure and, consequently, its clinical outcome. This study investigated the impact of hormonal status on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ximenez, João Paulo Bianchi, de Andrade, Jurandyr Moreira, Marques, Maria Paula, Coelho, Eduardo Barbosa, Suarez-Kurtz, Guilherme, Lanchote, Vera Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921430/ https://www.ncbi.nlm.nih.gov/pubmed/31852530 http://dx.doi.org/10.1186/s40360-019-0358-y

Ejemplares similares

Limited Sampling Modeling for Estimation of Phenotypic Metrics for CYP Enzymes and the ABCB1 Transporter Using a Cocktail Approach
por: Coelho, Eduardo Barbosa, et al.
Publicado: (2020)

Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.
por: Milano, G., et al.
Publicado: (1987)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

Proceedings: Hormones in breast cancer patients on tamoxifen.
por: Golder, M. P., et al.
Publicado: (1975)

Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer
por: Woo, Hye In, et al.
Publicado: (2017)

IARC on tamoxifen.
Publicado: (1996)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
por: Jager, Nynke GL, et al.
Publicado: (2013)

Leishmania is not prone to develop resistance to tamoxifen
por: Coelho, Adriano C., et al.
Publicado: (2015)

Tamoxifen and the Singing Voice
por: Herxheimer, Andrew
Publicado: (2005)

Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)

Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

Use of antipsychotics with tamoxifen
por: Ghabi, H., et al.
Publicado: (2021)

In Vivo Performance and Properties of Tamoxifen Metabolites for CreERT2 Control
por: Felker, Anastasia, et al.
Publicado: (2016)

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
por: Chen, Yuanhuang, et al.
Publicado: (2021)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer
por: Mo, Zhiqiang, et al.
Publicado: (2013)

The effect of tamoxifen on the genital tract
por: Polin, Sandra A., et al.
Publicado: (2008)

Hypertriglycéridémie majeure sous tamoxifène
por: Khabbal, Youssef, et al.
Publicado: (2012)

The Italian Tamoxifen Prevention Trial
por: Bonanni, B., et al.
Publicado: (1999)

Correction: Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

Tamoxifen-induced Lung Injury
por: Etori, Satoshi, et al.
Publicado: (2017)

Precautions for Patients Taking Tamoxifen
por: Heery, Mary, et al.
Publicado: (2018)

Acute Pancreatitis Caused by Tamoxifen-Induced Severe Hypertriglyceridemia After 4 Years of Tamoxifen Use
por: Tey, Tze Tong, et al.
Publicado: (2019)

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.
por: Lien, E. A., et al.
Publicado: (1991)

Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli
por: Miró-Canturri, Andrea, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance
por: Dickschen, Kristin, et al.
Publicado: (2012)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Evaluation of adverse effects in tamoxifen exposed healthy female dogs
por: Tavares, Wanessa LF, et al.
Publicado: (2010)

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene
por: Hachisuga, T, et al.
Publicado: (2005)

Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
por: Hind, D, et al.
Publicado: (2007)

Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance
por: Bekele, Raie T., et al.
Publicado: (2016)

The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient
por: Li, Chuanyu, et al.
Publicado: (2021)

Transporting Antitumor Drug Tamoxifen and Its Metabolites, 4-Hydroxytamoxifen and Endoxifen by Chitosan Nanoparticles
por: Agudelo, Daniel, et al.
Publicado: (2013)

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)

Histiocytic lymphoma of breast responds to tamoxifen.
por: Millis, R. R., et al.
Publicado: (1988)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_1s0kkj02j721fu8j032aub4128